Obama slams pharmas

Share this article:
Sen. Barack Obama (D-IL) feathered his bid for his party’s presidential nomination with a call for universal health coverage – and a swipe at the pharmaceutical industry. In an address this morning, Obama said: “Another, more controversial area we need to look at is how much of our healthcare spending is going toward the record-breaking profits earned by the drug and healthcare industry. It’s perfectly understandable for a corporation to try and make a profit, but when those profits are soaring higher and higher each year while millions lose their coverage and premiums skyrocket, we have a responsibility to ask why.” Obama’s chief rival, Sen. Hillary Clinton, was one of the industry’s top beneficiaries in the 2006 election cycle, receiving $119,225 from industry PACs and individual donors. She is expected to dust off some elements of her 1994 healthcare plan, which failed to win congressional approval, according to Washington trade The Hill.
Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...